Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Yin LiuLei FanZhong-Hua WangZhi-Ming ShaoPublished in: The oncologist (2022)
Nab-paclitaxel followed by dose-dense EC as NAC demonstrates promising anti-tumor activity and acceptable tolerability for patients with TNBC. (ClinicalTrials.gov Identifier: NCT03799679).
Keyphrases
- neoadjuvant chemotherapy
- phase ii study
- locally advanced
- open label
- rectal cancer
- squamous cell carcinoma
- advanced non small cell lung cancer
- sentinel lymph node
- radiation therapy
- lymph node
- placebo controlled
- low dose
- transcription factor
- high dose
- clinical trial
- chemotherapy induced
- double blind
- epidermal growth factor receptor